The latest announcements from Protagen, from our research programs to commercialization and partnerships—scroll down to find out more about what’s been happening in Dortmund and beyond.
Head of Communications
Dr Clare Russell
Managing Director, BioStrata, UK
T +44 1223 627121
Protagen AG. a leading provider of pharma development services, novel diagnostic tests and companion diagnostics in the fields of immuno-oncology and autoimmune disease, today announced changes to their Management Board. Dr. Georg Lautscham will join the...read more
Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, and Inova Diagnostics, a global leader in the development and commercialization of in-vitro diagnostic systems and reagents...read more
Protagen’s corporate leadership team combines over 40 years of commercial expertise and experience within the biotechnology industry, with a background spanning immunology, oncology, biomarker discovery and more.
Protagen is currently setting up an international scientific advisory board with key opinion leaders from the immuno-oncology and autoimmune disease fields. These expert panels will support our efforts in engaging with the medical and scientific community to develop products that are aimed at market needs.
Protagen has a number of established and committed investors, but is always looking at entering into new partnerships to help progress its research and commercialization efforts. If you are interested in investing in the company, please contact us.
Protagen is dedicated to the development of powerful diagnostic tools that aid successful therapeutic development and facilitate improved treatment strategies in the areas of autoimmune disease and immuno-oncology.
Here you will find our quarterly newsletter, “Stratified News from Dortmund”. With our newsletter we intend to regularly update you on developments at Protagen in a fresh and colorful format and we hope that you like it.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.